NZ721522A - Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists - Google Patents
Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonistsInfo
- Publication number
- NZ721522A NZ721522A NZ721522A NZ72152213A NZ721522A NZ 721522 A NZ721522 A NZ 721522A NZ 721522 A NZ721522 A NZ 721522A NZ 72152213 A NZ72152213 A NZ 72152213A NZ 721522 A NZ721522 A NZ 721522A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antagonists
- methods
- axis binding
- treating cancer
- vegf
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261653861P | 2012-05-31 | 2012-05-31 | |
NZ70278213 | 2013-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ721522A true NZ721522A (en) | 2018-03-23 |
Family
ID=61626678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ721522A NZ721522A (en) | 2012-05-31 | 2013-05-30 | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
Country Status (1)
Country | Link |
---|---|
NZ (1) | NZ721522A (en) |
-
2013
- 2013-05-30 NZ NZ721522A patent/NZ721522A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019003942A (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists. | |
ZA202110554B (en) | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors | |
PH12018500365A1 (en) | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors | |
MX2016007885A (en) | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody. | |
ZA201806633B (en) | Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors | |
HK1252149A1 (en) | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms | |
MX2017000546A (en) | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors. | |
HK1248608A1 (en) | Combinations of liposomal irinotecan, 5-fu and leucovorin for the treatment of pancreatic cancer | |
IL250187A0 (en) | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer | |
NZ718190A (en) | Substituted quinazolines for inhibiting kinase activity | |
MX2019013808A (en) | Compounds for treatment of cancer. | |
CA2908957C (en) | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer | |
IL247586A0 (en) | Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer | |
IL246880B (en) | A combination of oxalipatin, leucovorin and 5- fluorouracil for treating cancer | |
WO2013106460A3 (en) | Compositions and methods for treating malignant astrocytomas | |
NZ721522A (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
PL3010508T3 (en) | Combination of ro5503781, capecitabine and oxaliplatin for cancer therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAY 2020 BY THOMSON REUTERS Effective date: 20190417 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAY 2021 BY THOMSON REUTERS Effective date: 20200417 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAY 2022 BY THOMSON REUTERS Effective date: 20210403 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAY 2023 BY THOMSON REUTERS Effective date: 20220402 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAY 2024 BY THOMSON REUTERS Effective date: 20230403 |